Business Acquisition Agreement between Amsterdam Molecular Therapeutics (AMT) Holding N.V. as the Seller uniQure B.V. as the Purchaser Forbion Co-Investment II Coöperatief U.A. Coöperatieve AAC LS U.A. And FORBION Co-Investment COÖPERATIEF U.A. as the...Agreement • December 19th, 2013 • uniQure B.V. • Pharmaceutical preparations
[(1) Amsterdam Molecular Therapeutics (AMT) Holding N.V. a public company (naamloze vennootschap), incorporated under the laws of the Netherlands with its registered office (zetel) in Amsterdam, and its business address at Meibergdreff 61,105 BA, Amsterdam Zuidoost and registered with the Dutch Commercial Register (Handelsregister) of Amsterdam under number 33301321 (“Company”); and
DATED 16 February 2012 Amsterdam Molecular Therapeutics (AMT) B.V. and Amsterdam Molecular Therapeutics (AMT) IP B.V. as the Purchasers Amsterdam Molecular Therapeutics (AMT) Holding N.V. as the SellerAgreement • December 19th, 2013 • uniQure B.V. • Pharmaceutical preparations
Amsterdam Molecular Therapeutics (AMT) B.V., a company incorporated under the laws of the Netherlands with its corporate seat in Amsterdam, the Netherlands, registered with the trade register of the Chamber of Commerce with number 34275365;
DATED 5 APRIL 2012 Amsterdam Molecular Therapeutics (AMT) B.V. and Amsterdam Molecular Therapeutics (AMT) IP B.V. as the Transferees and Amsterdam Molecular Therapeutics (AMT) Holding N.V. as the TransferoruniQure B.V. • December 19th, 2013 • Pharmaceutical preparations
(Amsterdam Molecular Therapeutics (AMT) B.V. and Amsterdam Molecular Therapeutics (AMT) IP B.V. collectively also the “Transferees” and each individually a “Transferee”), and
